Use the hyperlinks, where available to access additional clinical trial information.
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)
Eligible participants will be randomly allocated to either the Experimental Arm or the Active Comparator Arm. In the Experimental Arm, participants will receive belzutifan (120mg) orally, once daily, in combination with pembrolizumab (400mg) administered via intravenous infusion (IV) once every 6 weeks, for approximately 54 weeks. In the Active Comparator Arm, participants will receive a daily oral placebo, in combination with pembrolizumab (400mg) via IV once every 6 weeks for approximately to 54 weeks.